All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How effective are JAK inhibitor combinations for patients with myelofibrosis?
Bookmark this article
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Srdan Verstovsek, MD Anderson Cancer Center, Houston, US. We asked, How effective are JAK inhibitor combinations for patients with myelofibrosis?
How effective are JAK inhibitor combinations for patients with myelofibrosis?
JAK inhibitors can control progressive symptomatic splenomegaly and disease-related symptoms; however, they may also worsen anemia in patients with myelofibrosis. Verstovsek outlines JAK inhibitor combinations of luspatercept, CPI-0610, navitoclax, and hypomethylating agents to help manage a wider range of symptoms.
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox